Pharmaceuticals

United States Drugs for Chronic Obstructive Pulmonary Disorder Market Report 2017

  • QYR907375
  • 115 Pages
  • February 2017
  • Pharmaceuticals
Download Sample    Get Discount   
 
Notes:

Sales, means the sales volume of Drugs for Chronic Obstructive Pulmonary Disorder

Revenue, means the sales value of Drugs for Chronic Obstructive Pulmonary Disorder

This report studies sales (consumption) of Drugs for Chronic Obstructive Pulmonary Disorder in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

AstraZeneca

Boehringer Ingelheim

GSK

Novartis

Teva Pharmaceuticals

Ache Laboratorios Farmaceuticos

Almirall

Aquinox Pharmaceuticals

Ario Pharma

Asmacure

Astellas Pharma

BioMarck Pharmaceuticals

Others

Market Segment by States, covering

California

Texas

New York

Florida

Illinois

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

Short-Acting Bronchodilators

Corticosteroids

Methylxanthines

Long-Acting Bronchodilators

Phosphodiesterase-4 Inhibitors

Split by applications, this report focuses on sales, market share and growth rate of Drugs for Chronic Obstructive Pulmonary Disorder in each application, can be divided into

GOLD 1? FEV1 ? 80%

GOLD 2? 50% ? FEV1 < 80%

GOLD 3? 30% ? FEV1 < 50%

GOLD 4? FEV1 < 30%

Table of Contents

United States Drugs for Chronic Obstructive Pulmonary Disorder Market Report 2017

1 Drugs for Chronic Obstructive Pulmonary Disorder Overview

1.1 Product Overview and Scope of Drugs for Chronic Obstructive Pulmonary Disorder

1.2 Classification of Drugs for Chronic Obstructive Pulmonary Disorder

1.2.1 Short-Acting Bronchodilators

1.2.2 Corticosteroids

1.2.3 Methylxanthines

1.2.4 Long-Acting Bronchodilators

1.2.5 Phosphodiesterase-4 Inhibitors

1.3 Application of Drugs for Chronic Obstructive Pulmonary Disorder

1.3.1 GOLD 1? FEV1 ? 80%

1.3.2 GOLD 2? 50% ? FEV1 < 80%

1.3.3 GOLD 3? 30% ? FEV1 < 50%

1.3.4 GOLD 4? FEV1 < 30%

1.4 United States Market Size Sales (Volume) and Revenue (Value) of Drugs for Chronic Obstructive Pulmonary Disorder (2012-2022)

1.4.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Growth Rate (2012-2022)

1.4.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2012-2022)

2 United States Drugs for Chronic Obstructive Pulmonary Disorder Competition by Manufacturers

2.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share of Key Manufacturers (2015 and 2016)

2.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Share by Manufactures (2015 and 2016)

2.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Average Price by Manufactures (2015 and 2016)

2.4 Drugs for Chronic Obstructive Pulmonary Disorder Market Competitive Situation and Trends

2.4.1 Drugs for Chronic Obstructive Pulmonary Disorder Market Concentration Rate

2.4.2 Drugs for Chronic Obstructive Pulmonary Disorder Market Share of Top 3 and Top 5 Manufacturers

2.4.3 Mergers & Acquisitions, Expansion

3 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales (Volume) and Revenue (Value) by States (2012-2017)

3.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share by States (2012-2017)

3.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by States (2012-2017)

3.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Price by States (2012-2017)

4 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales (Volume) and Revenue (Value) by Type (2012-2017)

4.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share by Type (2012-2017)

4.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Type (2012-2017)

4.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Price by Type (2012-2017)

4.4 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Type (2012-2017)

5 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales (Volume) by Application (2012-2017)

5.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share by Application (2012-2017)

5.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 United States Drugs for Chronic Obstructive Pulmonary Disorder Manufacturers Profiles/Analysis

6.1 AstraZeneca

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.1.2.1 Short-Acting Bronchodilators

6.1.2.2 Corticosteroids

6.1.3 AstraZeneca Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Boehringer Ingelheim

6.2.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.2.2.1 Short-Acting Bronchodilators

6.2.2.2 Corticosteroids

6.2.3 Boehringer Ingelheim Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 GSK

6.3.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.3.2.1 Short-Acting Bronchodilators

6.3.2.2 Corticosteroids

6.3.3 GSK Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Novartis

6.4.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.4.2.1 Short-Acting Bronchodilators

6.4.2.2 Corticosteroids

6.4.3 Novartis Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Teva Pharmaceuticals

6.5.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.5.2.1 Short-Acting Bronchodilators

6.5.2.2 Corticosteroids

6.5.3 Teva Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 Ache Laboratorios Farmaceuticos

6.6.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.6.2.1 Short-Acting Bronchodilators

6.6.2.2 Corticosteroids

6.6.3 Ache Laboratorios Farmaceuticos Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Almirall

6.7.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.7.2.1 Short-Acting Bronchodilators

6.7.2.2 Corticosteroids

6.7.3 Almirall Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Aquinox Pharmaceuticals

6.8.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.8.2.1 Short-Acting Bronchodilators

6.8.2.2 Corticosteroids

6.8.3 Aquinox Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

6.9 Ario Pharma

6.9.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.9.2.1 Short-Acting Bronchodilators

6.9.2.2 Corticosteroids

6.9.3 Ario Pharma Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 Asmacure

6.10.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification

6.10.2.1 Short-Acting Bronchodilators

6.10.2.2 Corticosteroids

6.10.3 Asmacure Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

6.11 Astellas Pharma

6.12 BioMarck Pharmaceuticals

6.13 Others

7 Drugs for Chronic Obstructive Pulmonary Disorder Manufacturing Cost Analysis

7.1 Drugs for Chronic Obstructive Pulmonary Disorder Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Drugs for Chronic Obstructive Pulmonary Disorder

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Drugs for Chronic Obstructive Pulmonary Disorder Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Drugs for Chronic Obstructive Pulmonary Disorder Major Manufacturers in 2015

8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 United States Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (2017-2022)

11.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue Forecast (2017-2022)

11.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Forecast by Type (2017-2022)

11.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Forecast by Application (2017-2022)

11.4 Drugs for Chronic Obstructive Pulmonary Disorder Price Forecast (2017-2022)

12 Research Findings and Conclusion

13 Appendix

Methodology

Analyst Introduction

Data Source

List of Tables and Figures

Figure Picture of Drugs for Chronic Obstructive Pulmonary Disorder

Table Classification of Drugs for Chronic Obstructive Pulmonary Disorder

Figure United States Sales Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by Type in 2015

Figure Short-Acting Bronchodilators Picture

Figure Corticosteroids Picture

Figure Methylxanthines Picture

Figure Long-Acting Bronchodilators Picture

Figure Phosphodiesterase-4 Inhibitors Picture

Table Application of Drugs for Chronic Obstructive Pulmonary Disorder

Figure United States Sales Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by Application in 2015

Figure GOLD 1? FEV1 ? 80% Examples

Figure GOLD 2? 50% ? FEV1 < 80% Examples

Figure GOLD 3? 30% ? FEV1 < 50% Examples

Figure GOLD 4? FEV1 < 30% Examples

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Growth Rate (2012-2022)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2012-2022)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales of Key Manufacturers (2015 and 2016)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Manufacturers (2015 and 2016)

Figure 2015 Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Manufacturers

Figure 2016 Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Manufacturers

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue by Manufacturers (2015 and 2016)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Manufacturers (2015 and 2016)

Table 2015 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Manufacturers

Table 2016 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Manufacturers

Table United States Market Drugs for Chronic Obstructive Pulmonary Disorder Average Price of Key Manufacturers (2015 and 2016)

Figure United States Market Drugs for Chronic Obstructive Pulmonary Disorder Average Price of Key Manufacturers in 2015

Figure Drugs for Chronic Obstructive Pulmonary Disorder Market Share of Top 3 Manufacturers

Figure Drugs for Chronic Obstructive Pulmonary Disorder Market Share of Top 5 Manufacturers

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales by States (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by States (2012-2017)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by States in 2015

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by States (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by States (2012-2017)

Figure Revenue Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by States (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Price by States (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales by Type (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Type (2012-2017)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by Type in 2015

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Type (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by Type (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Price by Type (2012-2017)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Type (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales by Application (2012-2017)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by Application (2012-2017)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by Application in 2015

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Application (2012-2017)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Application (2012-2017)

Table AstraZeneca Basic Information List

Table AstraZeneca Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Figure AstraZeneca Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Boehringer Ingelheim Basic Information List

Table Boehringer Ingelheim Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Boehringer Ingelheim Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table GSK Basic Information List

Table GSK Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table GSK Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Novartis Basic Information List

Table Novartis Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Novartis Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Teva Pharmaceuticals Basic Information List

Table Teva Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Teva Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Ache Laboratorios Farmaceuticos Basic Information List

Table Ache Laboratorios Farmaceuticos Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Ache Laboratorios Farmaceuticos Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Almirall Basic Information List

Table Almirall Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Almirall Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Aquinox Pharmaceuticals Basic Information List

Table Aquinox Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Aquinox Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Ario Pharma Basic Information List

Table Ario Pharma Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Ario Pharma Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Asmacure Basic Information List

Table Asmacure Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)

Table Asmacure Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)

Table Astellas Pharma Basic Information List

Table BioMarck Pharmaceuticals Basic Information List

Table Others Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Drugs for Chronic Obstructive Pulmonary Disorder

Figure Manufacturing Process Analysis of Drugs for Chronic Obstructive Pulmonary Disorder

Figure Drugs for Chronic Obstructive Pulmonary Disorder Industrial Chain Analysis

Table Raw Materials Sources of Drugs for Chronic Obstructive Pulmonary Disorder Major Manufacturers in 2015

Table Major Buyers of Drugs for Chronic Obstructive Pulmonary Disorder

Table Distributors/Traders List

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Production and Growth Rate Forecast (2017-2022)

Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate Forecast (2017-2022)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Production Forecast by Type (2017-2022)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Consumption Forecast by Application (2017-2022)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Forecast by States (2017-2022)

Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share Forecast by States (2017-2022)

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Similar Reports

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...

  • Publish Date: November 14, 2017
  • $5370
Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 - 2020

Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...

  • Publish Date: July 20, 2017
  • $5370